Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
6.20
+0.12 (1.89%)
Nov 21, 2024, 1:19 PM EST - Market open
Larimar Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 16.77 | 14.09 | 12.28 | 12.07 | 11.4 | 2.42 | |
| Research & Development | 56.99 | 27.67 | 24.25 | 38.4 | 31.41 | 20.79 | |
| Operating Expenses | 73.76 | 41.76 | 36.53 | 50.47 | 42.8 | 23.21 | |
| Operating Income | -73.76 | -41.76 | -36.53 | -50.47 | -42.8 | -23.21 | |
| Other Non Operating Income (Expenses) | 8.99 | 4.81 | 1.17 | -0.17 | 0.32 | 0.08 | |
| Pretax Income | -64.77 | -36.95 | -35.36 | -50.64 | -42.48 | -23.13 | |
| Net Income | -64.77 | -36.95 | -35.36 | -50.64 | -42.48 | -23.13 | |
| Net Income to Common | -64.77 | -36.95 | -35.36 | -50.64 | -42.48 | -23.13 | |
| Shares Outstanding (Basic) | 56 | 44 | 26 | 17 | 12 | 6 | |
| Shares Outstanding (Diluted) | 56 | 44 | 26 | 17 | 12 | 6 | |
| Shares Change (YoY) | 28.05% | 70.41% | 50.09% | 44.44% | 95.09% | - | |
| EPS (Basic) | -1.15 | -0.84 | -1.37 | -2.95 | -3.57 | -3.80 | |
| EPS (Diluted) | -1.15 | -0.84 | -1.37 | -2.95 | -3.57 | -3.80 | |
| Free Cash Flow | -58.79 | -33.62 | -27.67 | -42.44 | -42.26 | -22.78 | |
| Free Cash Flow Per Share | -1.04 | -0.77 | -1.07 | -2.47 | -3.56 | -3.74 | |
| EBITDA | -73.44 | -41.45 | -36.21 | -50.14 | -42.65 | -23.14 | |
| D&A For EBITDA | 0.32 | 0.31 | 0.32 | 0.33 | 0.16 | 0.08 | |
| EBIT | -73.76 | -41.76 | -36.53 | -50.47 | -42.8 | -23.21 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.